[앵커]
Allergy treatment, one of GI Innovation’s core pipelines, is discussing the contract size with three Japanese pharmaceutical companies, and technology transfer is being visualized. In addition, we plan to strengthen our competitiveness by establishing a new pipeline. Reporter Kim Hyo-sun reports.
[기자]
GI Innovation (CEO Byung-Gun Lee, Joon-Ho Hong)’s allergic disease treatment technology will be transferred to the Japanese market within this year.
On the 17th, the company held a press conference to explain the development progress of major pipelines and, in particular, technology transfer discussions for allergy disease treatment ‘GI-301’.
The company is currently actively collaborating with Yuhan in clinical/business development with the goal of global technology transfer of allergy treatment ‘GI-301’. It is a position to make it possible.
[이병건/ 지아이이노베이션 대표]
“I had a meeting with three Japanese companies at Bio USA last year. I am very interested. Term sheets are in the process of being exchanged, and we plan to complete the technology transfer as per our plan by the end of this year.”
According to the company, Japan currently has sales of 1 trillion won for hay fever and 3 trillion won for asthma and chronic obstructive pulmonary disease. Novartis’s Xolair is generating sales of 4 trillion won and Sanofi’s Dupicent is generating sales of 11 trillion won. However, as unmet demand is evident, the company’s treatment is expected to become a new alternative.
In addition, GI-101 and 102, immune anti-cancer drugs, which introduced a new process, are also spurring global clinical trials, and they are in a position to lead both intravenous and subcutaneous injections to the commercialization stage.
[이병건/ 지아이이노베이션 대표]
“Recently, we received approval for clinical change of 101A from the Ministry of Food and Drug Safety with an improved manufacturing method for 101. Then, we expect much better competition and better clinical results… Then, 102 will be clinically tested again in the US As this will progress, we are going to develop it in the future as a subcutaneous injection formulation. We intend to promote technology transfer as a company that has both intravenous injection formulation and subcutaneous injection formulation.”
In addition, the company announced that it has already completed the production of clinical raw materials for the 4th generation metabolic immuno-oncology drug ‘GI-108’ through collaboration with Samsung Biologics, and will apply for IND in the first half of next year to establish an item approval strategy.
This is Kim Hyo-sun from Pax Economy TV.
[촬영·편집: 장인식]
Copyright © Pax Economy TV Unauthorized reproduction and redistribution prohibited
2023-07-17 08:50:13
#영상 #Innovation #allergy #treatment #GI301 #countdown…Discussing #contract #size #Japanese #pharmaceutical #companies
